SCHEMBL5799604

SCHEMBL5799604

C1=CN(c2ccccc2)CN1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
ADRB1 P08588 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
MAPT P10636 3/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
BPTF Q12830 1/20 0.32
GAA P10253 2/20 0.32
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TSHR P16473 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925512 0.81 CHRNB2 (0.44) CYP3A4
SCHEMBL1925418 0.80 ADRB2 (0.41) MAPTNPSR1TSHRLMNATDP1
SCHEMBL15704762 0.78 SIGMAR1 (0.42) SIGMAR1HTR3EHTR3BADRB1HTR3A
SCHEMBL4538917 0.78 HTR3E (0.39) SIGMAR1HTR3EHTR3BADRB1HTR3A
SCHEMBL14889007 0.78 KMT2A (0.35) MAPTNPSR1NPC1RAB9AHPGD
SCHEMBL5802739 0.74 NPC1 (0.41) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL14889037 0.71 SIRT6 (0.47) ADRB1MAPTMEN1KMT2ALMNA
SCHEMBL1927670 0.71 MGLL (0.37) GSK3AGSK3B
SCHEMBL17766629 0.70 ALDH1A1 (0.44) MAPTNPSR1NPC1RAB9AHPGD
SCHEMBL10964131 0.70 SIGMAR1 (0.42) SIGMAR1HTR3EHTR3BADRB1HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106220625-A A kind of synthetic method of pirenzepine hydrochloride key intermediate 常州大学 2016-12-14 CN claimed
CN-101052640-A Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors APPLIED RESEARCH SYSTEMS (AN) 2007-10-10 CN claimed
CN-118290346-A Method for producing amide compound, and amide compound 广荣化学株式会社 2024-07-05 CN disclosed
CN-112703184-B Method for producing amide compound, and amide compound 广荣化学株式会社 2024-06-11 CN disclosed
US-11744142-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-08-29 US disclosed
CN-115197225-B Five-membered heterocyclic quinazolinone compound and preparation method thereof 贵州大学 2023-04-11 CN disclosed
CN-110396116-B [ N, O ] bidentate nickel and palladium complex of ketone-imidazoline-2-imine ligand, and preparation method and application thereof 东华大学 2020-07-28 CN disclosed
US-20190051845-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2019-02-14 US disclosed
CN-108349940-A Bruton's tyrosine kinase inhibitor 淄博百极常生制药有限公司 2018-07-31 CN disclosed
CN-107074769-A Compositions and methods for treating proliferative disorders 艾科尔公司 2017-08-18 CN disclosed
CN-106220625-A A kind of synthetic method of pirenzepine hydrochloride key intermediate 常州大学 2016-12-14 CN disclosed
US-20130303776-A1 LUMINESCENT MATERIAL, AND ORGANIC LIGHT-EMITTING ELEMENT, WAVELENGTH-CONVERTING LIGHT-EMITTING ELEMENT, LIGHT-CONVERTING LIGHT-EMITTING ELEMENT, ORGANIC LASER DIODE LIGHT-EMITTING ELEMENT, DYE LASER, DISPLAY DEVICE, AND ILLUMINATION DEVICE USING SAME SHARP KABUSHIKI KAISHA (JP) 2013-11-14 US disclosed
US-20130303777-A1 LUMINESCENT MATERIAL, AND ORGANIC LIGHT-EMITTING ELEMENT, WAVELENGTH-CONVERTING LIGHT-EMITTING ELEMENT, LIGHT-CONVERTING LIGHT-EMITTING ELEMENT, ORGANIC LASER DIODE LIGHT-EMITTING ELEMENT, DYE LASER, DISPLAY DEVICE, AND ILLUMINATION DEVICE USING SAME SHARP KABUSHIKI KAISHA (JP) 2013-11-14 US disclosed
US-20130284210-A1 SOLID FORMULATIONS, THEIR PREPARATION AND USE BASF SE (DE) 2013-10-31 US disclosed
CN-101052640-B Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors LABORATROIRES SERONO SA 2011-05-11 CN disclosed
CN-101925606-A Compounds comprising a cyclobutoxy group UCB PHARMA SA 2010-12-22 CN disclosed
CN-101052640-A Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors APPLIED RESEARCH SYSTEMS (AN) 2007-10-10 CN disclosed
EP-1692130-A2 PHENANTHRIDINIUM DERIVATIVES AS DNA BINDING AGENTS University Court of The University of Glasgow (GB) 2006-08-23 EP disclosed
US-6960601-B2 Preparation and use of imidazole derivatives for treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2005-11-01 US disclosed
WO-2005054241-A2 PHENANTHRIDINIUM DERIVATIVES AS DNA BINDING AGENTS THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744142-B2 Organic electroluminescent materials and devices TLL1, TLL2, ALPL SIGMAR1 2941/4885HTR3E 3028/4885HTR3B 3798/4885
US-20190051845-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES TLL1, TLL2, ALPL SIGMAR1 2941/4885HTR3E 3028/4885HTR3B 3798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.